These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 17702770)

  • 1. Efficacy and safety of interferon-alpha in the treatment of corticodependent uveitis of paediatric Behcet's disease.
    Guillaume-Czitrom S; Berger C; Pajot C; Bodaghi B; Wechsler B; Kone-Paut I
    Rheumatology (Oxford); 2007 Oct; 46(10):1570-3. PubMed ID: 17702770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients.
    Bodaghi B; Gendron G; Wechsler B; Terrada C; Cassoux N; Huong du LT; Lemaitre C; Fradeau C; LeHoang P; Piette JC
    Br J Ophthalmol; 2007 Mar; 91(3):335-9. PubMed ID: 17050581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human recombinant interferon alfa-2a for the treatment of Behçet's disease with sight threatening posterior or panuveitis.
    Kötter I; Zierhut M; Eckstein AK; Vonthein R; Ness T; Günaydin I; Grimbacher B; Blaschke S; Meyer-Riemann W; Peter HH; Stübiger N
    Br J Ophthalmol; 2003 Apr; 87(4):423-31. PubMed ID: 12642304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Experience of Interferon Alfa-2a Treatment for Refractory Uveitis in Behçet's Disease.
    Park JY; Chung YR; Lee K; Song JH; Lee ES
    Yonsei Med J; 2015 Jul; 56(4):1158-62. PubMed ID: 26069144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis associated with Behçet disease.
    Gueudry J; Wechsler B; Terrada C; Gendron G; Cassoux N; Fardeau C; Lehoang P; Piette JC; Bodaghi B
    Am J Ophthalmol; 2008 Dec; 146(6):837-44.e1. PubMed ID: 19027420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term Efficacy of Interferon in Severe Uveitis Associated with Behçet Disease.
    Diwo E; Gueudry J; Saadoun D; Weschler B; LeHoang P; Bodaghi B
    Ocul Immunol Inflamm; 2017 Feb; 25(1):76-84. PubMed ID: 27541620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Results of interferon alpha-2a therapy in patients with Behcet's disease.
    Yalçindağ FN; Uzun A
    J Ocul Pharmacol Ther; 2012 Aug; 28(4):439-43. PubMed ID: 22455657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Behçet's disease: uveitis-therapy with interferon alpha2a - prospective clinical study in 33 patients].
    Stübiger N; Kötter I; Deuter C; Zierhut M
    Klin Monbl Augenheilkd; 2001 Dec; 218(12):768-73. PubMed ID: 11805868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term remission after cessation of interferon-α treatment in patients with severe uveitis due to Behçet's disease.
    Deuter CM; Zierhut M; Möhle A; Vonthein R; Stöbiger N; Kötter I
    Arthritis Rheum; 2010 Sep; 62(9):2796-805. PubMed ID: 20518075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of ocular symptoms of Behçet's disease with interferon alpha 2a: a pilot study.
    Kötter I; Eckstein AK; Stübiger N; Zierhut M
    Br J Ophthalmol; 1998 May; 82(5):488-94. PubMed ID: 9713053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Ocular involvement in Behçet's disease: first 5-year-results for visual development after treatment with interferon alfa-2a].
    Deuter CM; Kötter I; Günaydin I; Zierhut M; Stübiger N
    Ophthalmologe; 2004 Feb; 101(2):129-34. PubMed ID: 14991308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term efficacy and safety of low-dose and dose-escalating interferon alfa-2a therapy in refractory Behçet uveitis.
    Onal S; Kazokoglu H; Koc A; Akman M; Bavbek T; Direskeneli H; Yavuz S
    Arch Ophthalmol; 2011 Mar; 129(3):288-94. PubMed ID: 21402983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longterm visual prognosis of patients with ocular Adamantiades-Behçet's disease treated with interferon-alpha-2a.
    Krause L; Altenburg A; Pleyer U; Köhler AK; Zouboulis CC; Foerster MH
    J Rheumatol; 2008 May; 35(5):896-903. PubMed ID: 18412306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-Term Efficacy of Pegylated Interferon Alpha-2b in Behçet's Uveitis: A Small Case Series.
    Celiker H; Kazokoglu H; Direskeneli H
    Ocul Immunol Inflamm; 2019; 27(1):15-22. PubMed ID: 28700247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term efficacy and safety of interferon α-2a therapy in severe refractory ophthalmic Behcet's disease.
    Kavandi H; Khabbazi A; Kolahi S; Hajialilo M; Shayan FK; Oliaei M
    Clin Rheumatol; 2016 Nov; 35(11):2765-2769. PubMed ID: 27234230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-interferon alpha antibodies and autoantibodies in patients with Behçet's disease uveitis treated with recombinant human interferon alpha-2a.
    Aydinoglu-Candan Ö; Araz-Erşan B; Gul A; Badur S; Tugal-Tutkun I
    Graefes Arch Clin Exp Ophthalmol; 2015 Mar; 253(3):457-65. PubMed ID: 25500983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of systemic recombinant interferon-alpha in Behçet's disease.
    Georgiou S; Monastirli A; Pasmatzi E; Gartaganis S; Goerz G; Tsambaos D
    J Intern Med; 1998 May; 243(5):367-72. PubMed ID: 9651559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of interferon alfa-2a in severe and refractory uveitis associated with Behçet's disease.
    Wechsler B; Bodaghi B; Huong DL; Fardeau C; Amoura Z; Cassoux N; Piette JC; LeHoang P
    Ocul Immunol Inflamm; 2000 Dec; 8(4):293-301. PubMed ID: 11262659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-TNF-α therapy in patients with refractory uveitis due to Behçet's disease: a 1-year follow-up study of 124 patients.
    Calvo-Río V; Blanco R; Beltrán E; Sánchez-Bursón J; Mesquida M; Adán A; Hernandez MV; Hernandez Garfella M; Valls Pascual E; Martínez-Costa L; Sellas-Fernández A; Cordero Coma M; Díaz-Llopis M; Gallego R; Salom D; García Serrano JL; Ortego N; Herreras JM; Fonollosa A; García-Aparicio AM; Maíz O; Blanco A; Torre I; Fernández-Espartero C; Jovani V; Peiteado-Lopez D; Pato E; Cruz J; Fernández-Cid C; Aurrecoechea E; García M; Caracuel MA; Montilla C; Atanes A; Hernandez FF; Insua S; González-Suárez S; Sánchez-Andrade A; Gamero F; Linares L; Romero-Bueno F; García AJ; Almodovar R; Minguez E; Carrasco Cubero C; Olive A; Vázquez J; Ruiz Moreno O; Jiménez-Zorzo F; Manero J; Muñoz Fernández S; Rueda-Gotor J; González-Gay MA
    Rheumatology (Oxford); 2014 Dec; 53(12):2223-31. PubMed ID: 24996907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term effects of interferon alpha 2A treatment in Behçet's disease.
    Boyvat A; Sişman-Solak C; Gürler A
    Dermatology; 2000; 201(1):40-3. PubMed ID: 10971058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.